{"brief_title": "Amprenavir/Ritonavir, Saquinavir/Ritonavir or Efavirenz in HIV-Infected Subjects Following Failure With Kaletra (ABT-378/Ritonavir) as Their First Protease Inhibitor Based HAART", "brief_summary": "The purpose of this study is to study amprenavir/ritonavir, saquinavir/ritonavir or efavirenz in HIV-infected patients following failure with Kaletra (ABT-378/ritonavir) as their first protease inhibitor based HAART.", "condition": ["HIV Infections"], "intervention_type": ["Drug", "Drug", "Drug"], "intervention_name": ["Amprenavir/ritonavir", "Saquinavir/ritonavir", "Efavirenz"], "criteria": "Inclusion: - Remain on present anti-HIV drugs during screening until a new regimen is started. - Have a viral load of at least 1,000 copies/ml on the 2 most recent tests after at least 24 weeks of lopinavir/ritonavir and while still on it. - Have an HIV which shows reduced susceptibility to lopinavir. - Are at least 18 years old. - Are not presently ill. - Have not been treated for an opportunistic infection within 30 days of screening. - Agree not to take certain drugs and agree to inform and get permission from the doctor before taking any medicines, over the counter medicines, herbal medicines, alcohol or recreational drugs. - Agree to use an accepted barrier method of birth control. Exclusion: - Female subject is pregnant or lactating. - Have taken any protease inhibitor other than lopinavir/ritonavir for more that two weeks. - Are taking chemotherapy. - Have a medical problem with their pancreas. - Have been screened for this study within the past 12 weeks. - Appear to be unsuitable in the opinion of the doctor.", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "keyword": "HIV", "mesh_term": ["HIV Infections", "Ritonavir", "Lopinavir", "HIV Protease Inhibitors", "Saquinavir", "Amprenavir", "Efavirenz", "Protease Inhibitors"], "id": "NCT00038532"}